Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

Researchers have discovered a novel biomarker in stable, ambulatory patients with heart failure with preserved ejection fraction (HFpEF), a finding which may lead to earlier diagnoses of HFpEF.

Guideline-directed medical therapies like beta-blockers and renin-angiotensin system blockers (RASBs)—but not aldosterone antagonists—are associated with improved outcomes in heart failure patients hospitalized with a midrange ejection fraction, researchers reported in the current edition of the Journal of the American Heart Association.

The National Institutes of Health (NIH) is pausing a taxpayer-funded, $63 million trial of cardiac stems cells over questions about the basis for the research.

Cardiac transplant candidates are better off accepting an organ with a higher risk of transmitting diseases than waiting for another heart, suggests a study published Oct. 29 in the Journal of the American College of Cardiology.

Omega-3 treatment was associated with significantly fewer gastrointestinal bleeding events for patients with left ventricular assist devices (LVADs), researchers reported in Circulation: Heart Failure.

Higher ejection fractions (EFs) among heart failure patients are associated with an increased incidence of atrial fibrillation (AF) and worse cardiovascular outcomes, according to data from a multinational European registry.

A small-scale pilot study has linked omega-3 fatty acid supplementation to improved social function and reduced cognitive depression in patients with combined chronic heart failure (CHF) and major depressive disorder.